| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/31/2011 | US20110077249 1,2,4-triazolylaminoaryl (heteroaryl) sulfonamide derivatives |
| 03/31/2011 | US20110077245 Substituted 2-alkyl quinazolinone derivatives as parp inhibitors |
| 03/31/2011 | US20110077242 Diaminopyrimidines as p2x3 and p2x2/3 antagonists |
| 03/31/2011 | US20110077241 Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
| 03/31/2011 | US20110077239 Glycine receptor agonists for the treatment of phantom phenomena |
| 03/31/2011 | US20110077238 Methods and compositions for deterring abuse |
| 03/31/2011 | US20110077237 Kinase inhibitors |
| 03/31/2011 | US20110077235 Apoptosis signal-regulating kinase 1 inhibitors |
| 03/31/2011 | US20110077232 Compositions comprising atorvastatin 4-(nitrooxy) butyl ester and a hypolipidemic drug |
| 03/31/2011 | US20110077226 Methods for Inhibiting the Development of Huntington's Disease |
| 03/31/2011 | US20110077224 Linoleic phospholipids and uses thereof for inhibiting inflammatory and neurodegenerative processes |
| 03/31/2011 | US20110077222 Sustained-Release Opiate and Opiate Derivative Compositions |
| 03/31/2011 | US20110077221 Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof |
| 03/31/2011 | US20110077220 4-oxo,1-4-dihydroquinoline m1 receptor positive allosteric modulators |
| 03/31/2011 | US20110077204 Agent for Targeted Drug Delivery To Cerebral Neurons |
| 03/31/2011 | US20110077200 Combination therapy using low-dose doxepin for the improvement of sleep |
| 03/31/2011 | US20110077194 Method for Treating or Preventing a Functional Vitamin B12 Deficiency in an Individual and to Medical Compositions for Use in Said Method |
| 03/31/2011 | US20110077190 Selective Caspase Inhibitors and Uses Thereof |
| 03/31/2011 | US20110076349 Composition containing hot-water extract of plant of the genus hemerocallis and having antidepressant-like effects or fatigue-relieving effects based on sleep improvement |
| 03/31/2011 | US20110076347 Molecules Interfering with Binding of Calbindin to Inositol Monophosphatase for the Treatment of Mood Disorders |
| 03/31/2011 | US20110076344 Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response |
| 03/31/2011 | US20110076330 Use of adipose tissue-derived stromal cells in spinal fusion |
| 03/31/2011 | US20110076326 Modified protein excipient for delayed-release tablet |
| 03/31/2011 | US20110076325 Abuse resistant drugs, method of use and method of making |
| 03/31/2011 | US20110076323 Vaccine for alzheimer's disease |
| 03/31/2011 | US20110076322 Amphoteric liposomes |
| 03/31/2011 | US20110076314 Hydrophobic polysaccharides with silyl ether linkages having enhanced degradation and medical articles made therefrom |
| 03/31/2011 | US20110076299 Novel immunogenic compositions for the prevention and treatment of meningococcal disease |
| 03/31/2011 | US20110076293 Triptolide derivatives for modulation of apoptosis and immunosuppression |
| 03/31/2011 | US20110076289 Transgenic animal model of neurodegenerative disorders |
| 03/31/2011 | US20110076269 Methods of increasing neuronal differentiation using antibodies to lysophosphatidic acid |
| 03/31/2011 | US20110076258 Methods of modulating t cell- dependent immune responses |
| 03/31/2011 | US20110076256 Human Neural Stem Cell and Pharmaceutical Composition for the Treatment of Central or Peripheral Nervous System Disorders or Injuries Using Same |
| 03/31/2011 | US20110076254 Porous scaffolds for stem cell renewal |
| 03/31/2011 | US20110076247 Agent comprising g-csf for prevention and treatment of diabetic peripheral neuropathy |
| 03/31/2011 | US20110076236 Compositions and methods of treatment using modulators of motoneuron diseases |
| 03/31/2011 | US20110076235 Genes, methods, and compositions related to neurogenesis and its modulation |
| 03/31/2011 | US20110076230 Novel Substituted Indoles |
| 03/31/2011 | CA2775328A1 Pyrido[4,3-b]indoles and methods of use |
| 03/31/2011 | CA2775323A1 Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process |
| 03/31/2011 | CA2775216A1 Bridged heterocyclic compounds and methods of use |
| 03/31/2011 | CA2775204A1 Fused imidazo [3, 2 - d] pyraz ines as pi3 kinase inhibitors |
| 03/31/2011 | CA2775133A1 Pyrido[3,4-b]indoles and methods of use |
| 03/31/2011 | CA2775129A1 Pyrido[3,4-b]indoles and methods of use |
| 03/31/2011 | CA2775027A1 Maleic acid salt and crystal thereof |
| 03/31/2011 | CA2774801A1 Use of nicotinic acetylcholine receptor alpha 7 activators |
| 03/31/2011 | CA2774647A1 Substituted amide compound |
| 03/31/2011 | CA2774569A1 Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents |
| 03/31/2011 | CA2774558A1 Methods and pharmaceutical compositions for treating down syndrome |
| 03/31/2011 | CA2774008A1 Toll-like receptor modulators and uses thereof |
| 03/31/2011 | CA2773305A1 Crystalline methylthioninium chloride hydrates |
| 03/31/2011 | CA2770278A1 Pyrazoline dione derivatives as nadph oxidase inhibitors |
| 03/30/2011 | EP2302391A1 Therapeutic and diagnostic uses of antibody specificity profiles in rheumatoid arthritis |
| 03/30/2011 | EP2302387A1 Therapeutic and diagnostic uses of antibody specificity profiles for insulin-dependent diabetes mellitus |
| 03/30/2011 | EP2302064A1 Method for producing biodegradable, functionalised polymer particles, and use of the same as medicament carriers |
| 03/30/2011 | EP2302039A1 Virus-like particles comprising HML-2 gag polypeptide |
| 03/30/2011 | EP2301971A1 Antibodies that bind both BCMA and TACI |
| 03/30/2011 | EP2301970A1 Human antibodies that bind human IL-12 and methods for producing |
| 03/30/2011 | EP2301960A2 Polymer conjugates of mutated neublastin |
| 03/30/2011 | EP2301951A1 Peptide derivative and composition for promoting tear secretion comprising the same |
| 03/30/2011 | EP2301938A1 Crystalline of eszopiclone, its composition, preparation and uses thereof |
| 03/30/2011 | EP2301936A1 Spirodiamine-diarylketoxime derivative |
| 03/30/2011 | EP2301934A1 Nitrocatechol derivatives as COMT inhibitors |
| 03/30/2011 | EP2301930A1 Thrombin receptor antagonists |
| 03/30/2011 | EP2301908A1 (-)-stereoisomer of 2,6-di-sec-butylphenol and analogs thereof for promoting antiemetic effect and treatment of nausea and vomiting |
| 03/30/2011 | EP2301625A2 Compositions and methods for treating cognitive disorders |
| 03/30/2011 | EP2301580A1 Anti-VEGF antibodies |
| 03/30/2011 | EP2301578A2 Methods for treating TWEAK-related conditions |
| 03/30/2011 | EP2301577A2 Methods for treating TWEAK-related conditions |
| 03/30/2011 | EP2301565A1 Use of proteasome inhibitors for the treatment of viral infections |
| 03/30/2011 | EP2301563A2 HSP20 peptides |
| 03/30/2011 | EP2301553A1 Polynucleotide therapy |
| 03/30/2011 | EP2301552A1 Polynucleotide therapy |
| 03/30/2011 | EP2301549A1 Remedies for diseases to be applied to eye |
| 03/30/2011 | EP2301542A1 Controlled-release compositions containing opioid agonist and antagonist |
| 03/30/2011 | EP2301534A1 Amino-methyl substituted tetracycline compounds |
| 03/30/2011 | EP2301532A1 Use of statins as anticonvulsants, antiepileptics and neuroprotectors |
| 03/30/2011 | EP2301527A1 Association of agomelatine with a mood stabilizer, and pharmaceutical compositions comprising them |
| 03/30/2011 | EP2301526A2 Morphine controlled release system |
| 03/30/2011 | EP2301494A1 Sustained analgesia achieved with buprenorphine |
| 03/30/2011 | EP2301493A1 Sustained analgesia achieved with buprenorphine |
| 03/30/2011 | EP2301343A1 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells |
| 03/30/2011 | EP2300499A1 Anti-prion protein antibody fragment |
| 03/30/2011 | EP2300484A1 Novel class of spiro piperidines for the treatment of neurodegenerative diseases |
| 03/30/2011 | EP2300481A2 Novel substituted azabenzoxazoles |
| 03/30/2011 | EP2300479A1 Nalmefene hydrochloride dihydrate |
| 03/30/2011 | EP2300474A1 Spiro (piperidine-4, 2 ' -pyrrolidine) -1- (3, 5- trifluoromethyl phenyl) methylcarboxamides as nk1 tachikynin receptor antagonists |
| 03/30/2011 | EP2300473A2 Fumarate salt of 4-bromophenyl 1,4-diazabicycloý3.2.2¨nonane-4-carboxylate, crystalline forms thereof, preparation thereof and therapeutic use thereof |
| 03/30/2011 | EP2300452A1 5-ý5-ý2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoylmethylamino¨-4-(4-fluoro-2-methylphenyl)¨-2-pyridinyl-2-alkyl-prolinamide as nk1 receptor antagonists |
| 03/30/2011 | EP2300432A1 Piperazine derivatives used as cav2.2 calcium channel modulators |
| 03/30/2011 | EP2300427A1 Urea compounds as gamma secretase modulators |
| 03/30/2011 | EP2300424A2 Use of indole derivatives as nurr-1 activators for treating parkinson s disease |
| 03/30/2011 | EP2300422A1 Azetidines and cyclobutanes as histamine h3 receptor antagonists |
| 03/30/2011 | EP2300044A1 Methods and compositions for the management of pain using omega-conotoxins |
| 03/30/2011 | EP2300039A2 ANXIOLYTIC COMPOSITION CONTAINING ALPHAs¹-CASEIN -DERIVED PEPTIDES |
| 03/30/2011 | EP2300030A2 Rice bran extracts and methods of use thereof |
| 03/30/2011 | EP2300029A2 Rice bran extracts for inflammation and methods of use thereof |
| 03/30/2011 | EP2300027A1 Method of treating migraine using guava |
| 03/30/2011 | EP2300015A1 Use of gabaa receptor antagonists for the treatment of excessive sleepiness and disorders associated with excessive sleepiness |
| 03/30/2011 | EP2300012A2 Method of treating peripheral nerve sensory loss using compounds having nicotinic acetylcholine receptor activity |